Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
Liaw B, Joshi H, Sheng T, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC. Journal Of Clinical Oncology 2024, 42: 147-147. DOI: 10.1200/jco.2024.42.4_suppl.147.Peer-Reviewed Original ResearchPSA response rateAlkaline phosphatase levelsStudy regimenImproved time to disease progressionPhosphatase levelsTime to disease progressionStandard managementResponse rateTreatment of mCRPCBaseline alkaline phosphatase levelsProlonged disease controlMinimize treatment toxicitySignificant antitumor responsesPrevent drug resistanceLong-term suppressionMedian TTPAntitumor responseMedian followTreatment toxicityPrimary endpointProstate cancerSecondary endpointsMCRPCTreatment regimenHeterogeneous disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply